Silk Road Medical, Inc. operates as a medical device company in the United States. It offers ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent with clinical data regarding lasting safety outcomes; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was founded in 2007 and is headquartered in Sunnyvale, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone408-720-9002
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$34.56 million
Profitability
Miscellaneous
Employees176
Next Earnings Date2/26/2020 (Confirmed)
OptionableNot Optionable
Silk Road Medical (NASDAQ:SILK) Frequently Asked Questions
What is Silk Road Medical's stock symbol?
Silk Road Medical trades on the NASDAQ under the ticker symbol "SILK."
How were Silk Road Medical's earnings last quarter?
Silk Road Medical Inc (NASDAQ:SILK) issued its quarterly earnings data on Tuesday, October, 29th. The company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.01. The company had revenue of $17 million for the quarter, compared to the consensus estimate of $15.93 million. The business's quarterly revenue was up 77.1% compared to the same quarter last year. View Silk Road Medical's Earnings History.
When is Silk Road Medical's next earnings date?
What guidance has Silk Road Medical issued on next quarter's earnings?
Silk Road Medical issued an update on its FY 2020
After-Hours earnings guidance on Wednesday, February, 26th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $92-95 million, compared to the consensus revenue estimate of $94.02 million.
What price target have analysts set for SILK?
5 brokerages have issued 12-month price objectives for Silk Road Medical's shares. Their forecasts range from $40.01 to $52.00. On average, they expect Silk Road Medical's share price to reach $44.80 in the next year. This suggests that the stock has a possible downside of 1.0%. View Analyst Price Targets for Silk Road Medical.
What is the consensus analysts' recommendation for Silk Road Medical?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Silk Road Medical in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Silk Road Medical.
Has Silk Road Medical been receiving favorable news coverage?
Media headlines about SILK stock have been trending extremely negative this week, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Silk Road Medical earned a news sentiment score of -4.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Silk Road Medical.
Are investors shorting Silk Road Medical?
Silk Road Medical saw a decline in short interest in February. As of February 14th, there was short interest totalling 1,140,000 shares, a decline of 6.6% from the January 30th total of 1,220,000 shares. Based on an average daily volume of 327,100 shares, the days-to-cover ratio is currently 3.5 days. Approximately 5.6% of the shares of the stock are sold short. View Silk Road Medical's Current Options Chain.
Who are some of Silk Road Medical's key competitors?
Some companies that are related to Silk Road Medical include Haemonetics (HAE), Globus Medical (GMED), Integra Lifesciences (IART), Tandem Diabetes Care (TNDM), ICU Medical (ICUI), Nevro (NVRO), NuVasive (NUVA), Cantel Medical (CMD), Irhythm Technologies (IRTC), Glaukos (GKOS), Merit Medical Systems (MMSI), Inspire Medical Systems (INSP), AtriCure (ATRC), Cardiovascular Systems (CSII) and Shockwave Medical (SWAV).
What other stocks do shareholders of Silk Road Medical own?
Who are Silk Road Medical's key executives?
Silk Road Medical's management team includes the folowing people:
- Ms. Erica J. Rogers, Chief Exec. Officer, Pres & Director (Age 55)
- Mr. Lucas W. Buchanan, Chief Financial Officer (Age 41)
- Mr. Robert A. Nicholas, VP of Operations & Engineering (Age 56)
- Mr. Andrew S. Davis, Exec. VP of Global Sales & Marketing (Age 50)
- Ms. Alison Highlander, VP of HR
When did Silk Road Medical IPO?
(SILK) raised $75 million in an initial public offering on Thursday, April 4th 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and BMO Capital Markets and Stifel were co-managers.
Who are Silk Road Medical's major shareholders?
Silk Road Medical's stock is owned by a number of of retail and institutional investors. Top institutional investors include Warburg Pincus LLC (19.13%), Janus Henderson Group PLC (6.25%), Alliancebernstein L.P. (4.73%), Bamco Inc. NY (4.41%), Jennison Associates LLC (3.97%) and Victory Capital Management Inc. (2.48%). Company insiders that own Silk Road Medical stock include Andrew S Davis, Erica J Rogers, Lucas W Buchanan, Pincus & Co Warburg, Richard Ruedy and X Finance LP Wp. View Institutional Ownership Trends for Silk Road Medical.
Which institutional investors are selling Silk Road Medical stock?
SILK stock was sold by a variety of institutional investors in the last quarter, including Warburg Pincus LLC, Janus Henderson Group PLC, Lord Abbett & CO. LLC, Schonfeld Strategic Advisors LLC, Credit Suisse AG, Nicholas Investment Partners LP, ArrowMark Colorado Holdings LLC and Advisor Group Inc.. Company insiders that have sold Silk Road Medical company stock in the last year include Andrew S Davis, Erica J Rogers, Lucas W Buchanan, Pincus & Co Warburg, Richard Ruedy and X Finance LP Wp. View Insider Buying and Selling for Silk Road Medical.
Which institutional investors are buying Silk Road Medical stock?
SILK stock was bought by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Alliancebernstein L.P., Cannell Peter B & Co. Inc., Parkman Healthcare Partners LLC, Jennison Associates LLC, Sectoral Asset Management Inc, Bamco Inc. NY and Massachusetts Financial Services Co. MA. View Insider Buying and Selling for Silk Road Medical.
How do I buy shares of Silk Road Medical?
Shares of SILK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Silk Road Medical's stock price today?
One share of SILK stock can currently be purchased for approximately $45.24.
How big of a company is Silk Road Medical?
What is Silk Road Medical's official website?
How can I contact Silk Road Medical?
Silk Road Medical's mailing address is 1213 INNSBRUCK DR., SUNNYVALE CA, 94089. The company can be reached via phone at 408-720-9002 or via email at [email protected]
MarketBeat Community Rating for Silk Road Medical (NASDAQ SILK)
MarketBeat's community ratings are surveys of what our community members think about Silk Road Medical and other stocks. Vote "Outperform" if you believe SILK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SILK will underperform the S&P 500 over the long term. You may vote once every thirty days.
